Literature DB >> 8726614

Percutaneous hepatic venous isolation and extracorporeal charcoal hemoperfusion for high-dose intraarterial chemotherapy in patients with colorectal hepatic metastases.

Y Ku1, M Tominaga, T Iwasaki, T Kitagawa, I Maeda, M Shiotani, S Kusunoki, Y Maekawa, M Samizo, T Fukumoto, Y Kuroda, S Hirota, Y Saitoh.   

Abstract

The results of treating 12 consecutive patients with unresectable colorectal hepatic metastases with a hepatic arterial infusion of high-dose Adriamycin, 100-120 mg/m2, using hepatic venous isolation (HVI) and charcoal hemoperfusion (CHP) are reported herein. Adriamycin was administered over 5-15 min under extracorporeal drug elimination by HVI-CHP. HVI was percutaneously accomplished by either the double-balloon technique using a Fogarty occlusion catheter (8/22F) or a balloon-tipped catheter (16F). During the infusion, isolated hepatic venous blood was filtered by CHP and pumped into the left axillary vein. There were no lethal complications, and good hemodynamic tolerance to HVI-CHP was confirmed. Tumor liquefaction accompanied by a sharp decrease in serum carcinoembryonic antigen levels by more than 50% of pretreatment levels was observed in 6 of the 12 patients 1 month after treatment. Apart from chemical hepatitis, which developed in 11 (92%) of the patients, the Adriamycin toxicities were well controlled following the development of nausea and vomiting in 2 patients (17%), leukopenia < 2,000/mm3 in 3 (25%), and gastric ulcer in 1 (8%). These results indicate that this method is a safe and useful procedure for otherwise hazardous high-dose intra-arterial chemotherapy in patients with unresectable hepatic tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726614     DOI: 10.1007/BF00311598

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  20 in total

1.  Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit.

Authors:  O CREECH; E T KREMENTZ; R F RYAN; J N WINBLAD
Journal:  Ann Surg       Date:  1958-10       Impact factor: 12.969

2.  [A comparative study of tumor responses of hepatocellular carcinoma and colorectal hepatic metastasis to cytotoxic anticancer drug].

Authors:  Y Ku; H Shiki; T Iwasaki; M Tominaga; Y Maekawa; M Samizo; T Fukumoto; T Kanamaru; T Nakamura; M Yamamoto
Journal:  Gan To Kagaku Ryoho       Date:  1993-08

3.  Extracorporeal carbon chemofiltration under hepatic venous isolation for high-dose intraarterial chemotherapy of the liver.

Authors:  Y Ku; Y Saitoh
Journal:  Surgery       Date:  1994-11       Impact factor: 3.982

4.  Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma.

Authors:  R S Leff; J M Thompson; D B Johnson; K R Mosley; M B Daly; W A Knight; R L Ruxer; G L Messerschmidt
Journal:  J Clin Oncol       Date:  1986-11       Impact factor: 44.544

5.  Extracorporeal cisplatin removal using direct hemoperfusion under hepatic venous isolation for hepatic arterial chemotherapy: an experimental study on pharmacokinetics.

Authors:  Y Maekawa; Y Ku; Y Saitoh
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

Review 6.  Intraarterial infusion of high-dose adriamycin for unresectable hepatocellular carcinoma using direct hemoperfusion under hepatic venous isolation.

Authors:  Y Ku; M Saitoh; T Iwasaki; M Tominaga; Y Maekawa; H Shiki; M Samizo; T Fukumoto; Y Kuroda; M Sako
Journal:  Eur J Surg Oncol       Date:  1993-08       Impact factor: 4.424

7.  New preoperative chemotherapy for bladder cancer using combination hemodialysis and direct hemoperfusion: preliminary report.

Authors:  S Kamidono; A Fujii; G Hamami; Y Nakano; K Umezu; Y Oda; J Ishigami
Journal:  J Urol       Date:  1984-01       Impact factor: 7.450

8.  Regional chemotherapy of colorectal cancer metastatic to the liver.

Authors:  J E Niederhuber; W Ensminger; J Gyves; J Thrall; S Walker; E Cozzi
Journal:  Cancer       Date:  1984-03-15       Impact factor: 6.860

9.  [Balloon occluded arterial infusion therapy for malignant hepatic tumors].

Authors:  M Kawabata; S Takashima; K Mitsuzane; M Tanaka; C Maeda; J Hamachi; S Nomura; M Toshiyuki; N Kobayashi; M Sato
Journal:  Gan To Kagaku Ryoho       Date:  1984-04

10.  Clinical pilot study on high-dose intraarterial chemotherapy with direct hemoperfusion under hepatic venous isolation in patients with advanced hepatocellular carcinoma.

Authors:  Y Ku; T Fukumoto; T Iwasaki; M Tominaga; M Samizo; T Nishida; Y Kuroda; S Hirota; M Sako; H Obara
Journal:  Surgery       Date:  1995-05       Impact factor: 3.982

View more
  2 in total

1.  Induction of long-term remission in advanced hepatocellular carcinoma with percutaneous isolated liver chemoperfusion.

Authors:  Y Ku; T Iwasaki; T Fukumoto; M Tominaga; S Muramatsu; N Kusunoki; T Sugimoto; Y Suzuki; Y Kuroda; Y Saitoh; M Sako; S Matsumoto; S Hirota; H Obara
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

2.  Evaluation of Delcath Systems' Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion.

Authors:  Fred M Moeslein; Elizabeth G McAndrew; William M Appling; Nicole E Hryniewich; Kevin D Jarvis; Steven M Markos; Timothy P Sheets; Rajneesh P Uzgare; Daniel S Johnston
Journal:  Cardiovasc Intervent Radiol       Date:  2014-01-09       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.